Used for post-surgical inflammation with moderate IOP risk.
For severe inflammation but higher IOP risk.
Lower IOP risk, quick breakdown in ocular tissue.
Intense inflammation, high cost, high IOP risk.
Mild irritation, minimal IOP risk.
FML Forte is a brand‑name ophthalmic suspension containing 0.1% fluorometholone, a synthetic corticosteroid that reduces ocular inflammation by inhibiting cytokine production. Marketed primarily for post‑operative inflammation after cataract or LASIK surgery, it offers a balance between efficacy and a relatively low risk of raising intra‑ocular pressure (IOP). The drug is typically prescribed as one drop four times daily for the first week, tapering over 2‑3 weeks depending on the surgeon’s protocol.
Fluorometholone belongs to the class of corticosteroids but is considered medium‑potency compared with prednisolone (higher) or hydrocortisone (lower). Its chemical structure includes a fluorine atom that enhances anti‑inflammatory activity while slightly reducing mineralocorticoid effects, which translates into a modest IOP rise in most patients.
When doctors consider alternatives, they usually look at the same therapeutic goal-controlling inflammation-while balancing potency, side‑effects, cost, and dosing convenience. Below are the most common substitutes.
This is a high‑potency steroid (1% suspension) often used for severe inflammation such as uveitis or aggressive post‑op swelling. It has a faster onset than fluorometholone but carries a higher risk of IOP spikes, especially with prolonged use.
Loteprednol is a “soft” steroid designed to break down quickly in ocular tissues, reducing long‑term side effects. Available as 0.5% drops (e.g., Lotemax), it offers comparable efficacy to prednisolone for many cases but with a markedly lower tendency to raise IOP.
Dexamethasone (0.1% or 0.125% solution) is a very high‑potency steroid frequently reserved for intense inflammation like postoperative endophthalmitis. Its strength makes it effective quickly, yet the price point and side‑effect risk are also the highest among topical steroids.
Hydrocortisone 0.5% or 1% is the lowest‑potency steroid, mainly used for mild allergic conjunctivitis or superficial irritation. It rarely raises IOP, making it a safe first‑line option when inflammation is minimal.
While not a steroid, bromfenac is a non‑steroidal anti‑inflammatory drug (NSAID) eye drop (0.09%) often paired with low‑potency steroids after cataract surgery to control pain and inflammation without adding steroid‑related side effects.
Brand / Generic | Potency | Typical Dose | Onset of Action | Common Side Effects | Average US Price (per bottle) |
---|---|---|---|---|---|
FML Forte (Fluorometholone) | Medium | 1 drop 4×/day, taper 2-3weeks | 12-24hrs | Mild IOP rise, temporary burning | $25-$30 |
Prednisolone acetate | High | 1 drop 4-6×/day, taper 4-6weeks | 6-12hrs | IOP spikes, cataract progression | $15-$20 |
Loteprednol etabonate | Medium‑low | 1 drop 4×/day, taper 2-4weeks | 12-18hrs | Very low IOP increase, mild irritation | $35-$45 |
Dexamethasone | Very high | 1 drop 4×/day, short course (5‑7days) | Within 4-6hrs | Significant IOP rise, cataract risk | $20-$25 |
Hydrocortisone | Low | 1 drop 3-4×/day, as needed | 24-48hrs | Rarely elevates IOP, possible stinging | $8-$12 |
Not every steroid fits every eye condition. Below are common clinical situations and the most suitable choice based on the table above.
Most surgeons advise a taper of 2-3weeks. If inflammation persists, a follow‑up exam is needed to decide whether to continue, switch, or stop.
Long‑term high‑dose steroid use can accelerate cataract formation, but short post‑op courses of fluorometholone rarely cause this issue.
Yes, many clinicians step down to a lower‑potency steroid once inflammation is under control. The switch should be done gradually to avoid rebound swelling.
A mild burning or gritty feeling is common. If it persists for more than a day or worsens, rinse the eye with sterile saline and contact your ophthalmologist.
Generic formulations contain the same active ingredient and concentration, so efficacy is comparable. However, preservative type and bottle design can affect tolerability for some patients.
© 2025. All rights reserved.
Comments
Jo D
Wow, because a 0.1% fluorometholone droplet is basically the holy grail of ocular micro‑nano‑pharmaco‑dynamics, right?
On October 4, 2025 AT 02:50